1stOncology™: Cancer Intelligence Service – Page 14642 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference

On March 5, 2019 Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the 39th Annual Cowen & Co.Health Care Conference on Tuesday, March 12, 2019 at 8:40 a.m. ET (Press release, Blueprint Medicines, MAR 5, 2019, Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference [SID1234533970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference

On March 5, 2019 Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, reported that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the Cowen and Company 39th Annual Health Care Conference at 8:00 am ET on Tuesday, March 12, 2019 in Boston, MA (Press release, Alder Biopharmaceuticals, MAR 5, 2019, https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-present-cowen-and-company-39th-annual [SID1234533969]).

The presentation will be webcast live on the Events & Presentations page of the Investors section of Alder’s website at View Source, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after the live event concludes.

Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference

On March 5, 2019 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time (Press release, Seattle Genetics, MAR 5, 2019, View Source [SID1234533968]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Inovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019

On March 5, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that 2018 fourth quarter and full year financial results will be released after the market close on March 12, 2019 (Press release, Inovio, MAR 5, 2019, View Source [SID1234533967]). Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET, to provide a general business update, financial results, and 2019 cash burn guidance.

A live and archived version of the audio presentation will be available online at View Source This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible one hour after the call at 877-344-7529 (domestic) or 412-317-0088 (international) using replay access code 10129375.

Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 – 19, 2019

On March 5, 2019 Propanc Biopharma, Inc. (OTCQB:PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, reported that its Chief Executive Officer, James Nathanielsz, has been invited to present at the 31st Annual ROTH Conference being held on March 17 – 19, 2019 at the Ritz Carlton, Laguna Niguel located in Orange County, California (Press release, Propanc, MAR 5, 2019, View Source [SID1234533966]).

The conference will feature presentations from public and private companies across a variety of industry sectors and is one of the largest of its kind in the US. Last year, the ROTH Conference hosted close to 550 participating companies and more than 4,700 attendees, including institutional investors, analysts, family offices and high net worth investors.

Mr. Nathanielsz is scheduled to present in one-on-one meetings with institutional analysts and investors throughout the day on March 19. He will be discussing Propanc’s plans for advancing its lead product, PRP, towards human trials this year.

ROTH will host a pre-recorded webcast of Propanc’s presentation, which will be available on the conference website at View Source beginning on March 11.

Investors and potential partners attending the conference who wish to meet with Propanc’s management can contact their ROTH representative. For those not planning to attend the conference, please contact Lisa DeScenza to set up a call with Mr. Nathanielsz to learn more about Propanc.